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Epithelial ovarian cancer stem cells (EOC stem cells) have been associated with recurrence and chemoresistance. CD44 and CK18
are highly expressed in cancer stem cells and function as tools for their identiﬁcation and characterization. We investigated the
association between the number of CD44+ EOC stem cells in ovarian cancer tumors and progression-free survival. EOC stem
cells exist as clusters located close to the stroma forming the cancer stem cell “niche”. 17.1% of the samples reveled high number
of CD44+ EOC stem cells (>20% positive cells). In addition, the number of CD44+ EOC stem cells was signiﬁcantly higher in
patients with early-stage ovarian cancer (FIGO I/II), and it was associated with shorter progression-free survival (P = 0.026).This
study suggests that quantiﬁcation of the number of EOC stem cells in the tumor can be used as a predictor of disease and could be
applied for treatment selection in early-stage ovarian cancer.
1.Introduction
Epithelial ovarian cancer (EOC) is the fourth leading cause
of cancer-related deaths in women in the United States and
the leading cause of gynecologic cancer deaths with a 5-year
survival of only 30–40% [1–5]. Most patients are diagnosed
with advanced-stage disease and the majority recurs despite
optimal surgical debulking and initial response to chemo-
therapy. Recurrence is almost always accompanied by the de-
velopment of chemoresistance and carcinomatosis, which
may not be amenable to surgery [2]. Thus, patients with re-
current ovarian cancer usually succumb to the disease.
Current studies suggest that the tumor is initiated and
maintained by a unique population of cells with stem-like
properties[6].Thecancerstemcell(CSC)hypothesisimplies
that the inherently chemoresistant CSC can persist after
chemotherapy and repopulate the tumor leading to recur-
rence [7–10]. Contrary to the stochastic model of cancer
(clonal expansion), the Cancer Stem Cell model holds that
tumors are hierarchically organized and only some cells have
the capacity to indeﬁnitely self-renew and sustain tumor
growth [11, 12]. It is thought that CSCs are able to sur-
vive conventional chemotherapies, which usually target fast
dividing cells, and giverise torecurrent tumorsthatare more2 Journal of Oncology
resistant and more aggressive [13]. Thus, detection of the
CSCpopulation has implications for the diagnosis and treat-
ment of most cancers.
One of the major problems in elucidating the cellular
origin and pathogenesis of ovarian cancer is that it is a heter-
ogeneous disease. Indeed, ovarian cancer can be classiﬁed
into multiple types (serous, endometrioid, clear cell, and
mucinous), with each type having widely diﬀerent clinico-
pathologic properties. It is therefore possible that each of
these types of ovarian cancer has diﬀerent cellular origin.
Consequently, the CSC population for each type may also
be variable. It is therefore not surprising that stem cell
properties havebeen reported inovarian cancercells isolated
using diﬀerentcell surface markers, includingCD44,CD133,
orCD24[14–21].Each ofthese ovariancancercell typesmay
represent either a hierarchy of CSC or an entirely diﬀerent
population of CSC for that particular ovarian histotype.
Recently we, and others, demonstrated the presence of
epithelial ovarian cancerstem cells (EOCstem cells) in tissue
samples and cell lines [16–19, 22]. Several markers have been
used for the identiﬁcation of EOC stem cells, which reﬂect
the heterogeneity of ovarian cancer. These markers include
CD44,CD133,CD24,ALDH1,MyD88,andCD117.Ofthese
markers, the cell surface protein CD44 has been most ex-
tensively described to potently enrich the EOC stem cells.
CD44+ EOC stem cells express pluripotency markers such
as β-catenin, Oct-4, and SSEA-4 [14] and have been demon-
strated to be the chemoresistant progenitors in vivo and are
able to diﬀerentiate into the heterogenous cell types com-
prising the tumor [14, 22].
The objectives of the present study were twofold: (i) to
characterize the location of CD44+ EOC stem cells in tissue
samples and (ii) to determine whether the CD44+ EOC
stemcell“load”correlateswithclinicalparametersinovarian
cancer patients. Using ovarian cancer tissue sections from
117 patients with primary disease, we investigated the rela-
tionship between the number of CD44+ EOC stem cells and
various clinical parameters, which include chemoresponse
and progression-free survival.
2.Materialsand Methods
2.1. Ovarian Cancer Cells. The experiments described here
were performed using ﬁve EOC stem cells (CD44+) and
ﬁve mature ovarian cancer cells (mEOC cells, CD44−)t h a t
our laboratory isolated and established from either ascites or
ovarian tumors [14]. mEOC cells correspond to the CD44−
component of the tumor or from cells derived from CD44+
EOC cells following in vitro and in vivo diﬀerentiation. We
found the same characteristics in CD44− cells isolated from
the original tumor or CD44− cells originated from CD44+
EOC cells following in vitro and in vivo diﬀerentiation [15].
We generated ﬂuorescence-labeled EOC stem cell clones
by stable transfection with lentiviral constructs expressing
the red ﬂuorescence protein Tomato under the ubiquitin
promoter-driven L2G (pFU-L2T) as described elsewhere
[23].Thisconstructledtothemosteﬃcientorstablelabeling
and brightest bioluminescent signal [24].
2.2. Protein Preparation. Protein extraction was done as pre-
viously described[25].Brieﬂy,cell pelletswere lysedonicein
1× phosphate-buﬀered saline with 1% NP40, 0.1% SDS and
freshly added 20mL/mL protease inhibitor cocktail (Sigma
Chemical, St Louis, MO, USA) and 2mM phenylmethyl-
sulfonyl ﬂuoride (Sigma Chemical). Protein concentration
wasdeterminedbyBCAProteinAssay(PierceBiotechnology,
Rockford, IL, USA), and proteins were stored at −80◦Cu n t i l
further use.
2.3. SDS–PAGE and Western Blots. Aq u a n t i t yo f2 0 μgo f
each protein sample was denatured in sample buﬀer and
subjected to 12% SDS-polyacrylamide gel electrophoresis
(PAGE) aspreviously described[25].The following antibody
dilutions were used: CD44 antibody (1:2000) MEM-263
(Novus Biologicals, Littleton, CO, USA), monoclonal Ck18
antibody DC10 (1:1000) (Cell Signaling, Danvers, MA,
USA), and rabbit anti-human β-actin (1:10,000). Speciﬁc
protein bands were visualized using enhanced chemilumi-
nescence (Pierce Biotechnology).
2.4.FlowCytometry. Flowcytometryanalysis wasperformed
as previously described [14]. Brieﬂy, cells were trypsinized
and pelleted cells were incubated with either PE-anti CK18
or APC-anti CD44 antibodies (eBioscience, San Diego, CA).
Data was acquired using BD FACS Calibur and analyzed
using Cell Quest Pro (BD Bioscience).
2.5. Study Population. Tumor tissue and patients’ clinical
data were collected from a prospective translational research
protocol. The patients were all newly diagnosed with ovarian
cancer and referred forﬁrst-line platinum-based chemother-
apy at the departments of clinical oncology at Vejle, Aalborg,
Odense, and Herning Hospitals. Collected data were entered
into case report forms and all tumor specimens underwent
central pathology evaluation. Patients received both oral
and written study-related information before they signed
a consent form prior to collection of biological material.
The Danish Biomedical Research Ethics Committee and the
Danish Data Protection Agency approved the study.
A majority of the patients underwent primary debulking
surgery, while a minor portion (N = 3, 2.6%) were treated
with neoadjuvant chemotherapy. All the patients in this
cohort received ﬁrst-line combination chemotherapy with
carboplatin (AUC5) and paclitaxel (175mg/m2). Treatment
was administered every 3 weeks for at least four cycles.
Response to chemotherapy was assessed according to GCIG
CA125criteria[26,27]and/orRECISTcriteriabyCTorMRI
scans.
2.6. CD44 and Ck18 Immunohistochemical Staining. Forma-
lin-ﬁxed, paraﬃn-embedded tissue blocks obtained during
primary tumor debulking and prior to ﬁrst-line chemother-
apy were used for immunohistochemical staining for CD44
or Ck18 (Cell Signaling) 1:100 dilution. The slides from
the primary debulking operations were collected from nine
regional Danish Departments of Pathology and underwent
central pathologyrevision (MW).The tumorswere classiﬁedJournal of Oncology 3
according to the WHO histological classiﬁcation and graded
accordingtoShimizu etal. [28].Onerepresentativeparaﬃn-
embeddedformalin-ﬁxedtumorblockfromeachpatientwas
selectedand4μmsectionswerecutandstoredat−80◦Cuntil
further analysis. One section from each patient was used
for IHC with monoclonal CD44 antibody (1:2000) MEM-
263(NovusBiologicals,Littleton,CO,USA)and monoclonal
Ck18 antibody DC10 (1:1000) (Cell Signaling, Danvers,
MA, USA).
In brief, the sections were deparaﬃnized in Tissue clear
(Tissue Tec, Sakura Finetek, Zoeterwoude, Netherlands) fol-
lowed by washes in a graded series of ethanol for rehy-
dration in Tissue Tec Prism (Sakura, Prohosp, Vaerloese,
Denmark). The sections were then treated with 3% H2O2 to
block endogenous peroxidase activity. Heat-induced epitope
retrieval was done in a microwave oven using TEG pH 9.0
with 15 minutes boiling and 15 minutes for cooling down.
The sections were incubated with the primary antibody in
1% bovine serum albumin/tris-buﬀered saline for 30 min-
utes at room temperature. Immunohistochemical staining
was performed by the Autostainer Plus Link (AS 10030
DAKO, Glostrup, Denmark) according to manufacturer’s
instruction. DAKO Envision+ (DAKO, Glostrup, Denmark)
was used for antibody detection and was followed by visu-
alization with DAB+ (DAKO, Glostrup, Denmark). After
washing, the reaction was enhanced by 0.5% copper sul-
phate in TBS for 10 minutes, and the slides were counter-
stained with Mayers sour hematoxyline before dehydration
and mounting.
To validate the immunohistochemical procedure, nega-
tive and positive controls were included in each run. A small
tissue microarray containing ovarian tumors was used to-
gether with tissue from appendix and tonsil for positive
controls. The same tissue was incubated in 1% bovine serum
albumin/tris-buﬀered saline but without the primary anti-
body for negative control.
2.7. Evaluation of CD44 Immunohistochemical Staining. The
study pathologist (MW) scored all the samples: the whole
tumor slide was evaluated, and the percentage of CD44
positive stained cells was divided into 0%, >0–5%, >5%–
10%, >10%–20%, >20%–50%,and >50%. Forclassiﬁcation,
we divided the patients into those with <20% CD44+ cells
and those with >20% CD44+ cells.
2.8. Statistical Analyses. The correlation between CD44 ex-
pression and clinicopathological parameters was assessed
by χ2 statistics and the same applied to the association
between CD44 expression and response to chemotherapy.
Progression-free survival was deﬁned as the elapsed time
from date of diagnosis (date of primary surgery) until
progression or death attributable to any cause. Univariate
progression-free survival analysis was performed using the
Kaplan-Meier estimates and log-rank statistics for compari-
son of survival plots. Multivariate progression-free survival
analysis was determined by the Cox regression model. The
parameters entered in the Cox analysis were CD44 status
(Low expression: <20% positive cells; high expression: >20%
positive cells), FIGO stage, grade, and residual tumor as
categorical variables, and age at diagnosis as a continuous
variable. Statistical analyses were performed with the NCSS
software (version 2007, Kaysville, Utah, http://www.ncss
.com/). A value of P<0.05 was considered statistically sig-
niﬁcant.
3.Results
3.1. Characteristics of Ovarian Cancer Stem Cells. We previ-
ously demonstrated that the ovarian cancer stem cells are
CD44+, represent the chemoresistant population, and are
able to diﬀerentiate in vitro and in vivo to CD44− cells [14].
Recent studies have shown that ovarian cancer stem cells are
also ALDH1+. Therefore, we evaluated ALDH1 expression
on CD44+ and CD44− EOC cells. As shown in Figure 1,
CD44+, but not CD44−, EOC cells express high levels of
ALDH1, further conﬁrming that the CD44+ EOC stem cells
express the majority of identiﬁed markers for tumor initiat-
ing cells (Figure 1)[ 15, 21].
To closely monitor the process of diﬀerentiation, we la-
beled pure clones of CD44+ EOC cells with a ﬂuorescent
reporter, which allows ﬂow cytometry analysis and in vivo
imaging. Thus, CD44+ EOC stem cell clones were stably
transfected withaviral vectorexpressing theredﬂuorescence
protein “Tomato” (pFU-L2T) [23]. CD44+/Tomato+ EOC
cells were injected into nude mice, and the established tumor
(60 days later) was evaluated for CD44 and Tomato. As
shown in Figure 2, prior to injection the EOC stem cells
are 99.5% CD44+/Tomato+. The xenograft established,
however, is only 4.5 % CD44+/Tomato+ and 95.5% CD44−/
Tomato+. These results demonstrate that the CD44− cells
originated from the CD44+/Tomato+ EOC cells (Figure 2).
3.2. Cytokeratin 18 (Ck18) Is Preferentially Expressed by the
EOC Stem Cells. We previously showed, using gene expres-
sion microarray, that Ck18 expression is 7-fold higher
(P = 0.0007) in CD44+/MyD88+ EOC stem cells compared
to the CD44−/MyD88− mature ovarian cancer stem cells
(mOCCs) [14]. To validate this ﬁnding, we determined the
levels of Ck18 in ﬁve EOC stem cell clones, three mOCC
clones, and in the EOC cell line A2780 using western blot
analysis. As shown in Figure 3, Ck18 expression is limited to
theEOCstemcellsandnotthemOCCs.Correlationbetween
CD44 and Ck18 expression was also observed by ﬂow
cytometry and western blot (Figures 3(a), 3(b)). Evaluation
of the location of CD44+ and Ck18+ cells in tumor tissues
obtained from ovarian cancer patients showed that CD44+
(Figures 3(c), 3(d)) and Ck18+ cells (Figures 3(e), 3(f))
are surrounded by CD44-/Ck18− mOCCS. Within tumor
nests, single (Figure 4(a)) and clusters (Figures 4(b)–4(d))
of Ck18+ cancer cells were observed. These cells morpho-
logically appear less diﬀerentiated with larger size, higher
nuclear to cytoplasm (N/C) ratio, more prominent nucleoli,
and a vesicular chromatin pattern (Figure 5). In cells with
am o r ed i ﬀerentiated phenotype (smaller size and lower
N/C ratio), Ck18 staining was weak to absent (Figures 3
and 4). Some of the Ck18+ clusters were observed in close4 Journal of Oncology
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Figure 1: Correlation of CD44 and ALDH1 Expression in epithelial ovarian cancer stem cells. A panel of ovarian cancer cells was evaluated
for the expression of CD44 and ALDH1 by immunoﬂuorescence. Only CD44+ EOC stem cells are also positive for ALDH1 expression.
representative ﬁgure of ﬁve independent experiments using ﬁve clones of CD44+ cells and their derived CD44− cells.
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Figure 2: CD44+ EOCcells undergo in vivo diﬀerentiation into CD44− cells. Flowcytometry analysisofCD44+ cells stabletransfected with
a lentivirus expressing the ﬂuorescent protein Tomato (red). (a) Cells prior to injection into the mice are 99.5% double positive for CD44
and Tomato. (b) 95.5% of the cells isolated from the tumor remain positive for the ﬂuorescence protein Tomato but are negative to CD44.
Only 4.5% of the injected cells remained double positive.
proximity to the stroma and showed a clear and deﬁned
basal membrane (Figure 5). The observed distribution of the
Ck18+ cancer cells follows the description of the niche as-
sociated with CSC [9, 29]. A similar pattern of localization
was observed with CD44 staining [14].
3.3. Variable Expression of CD44+ EOC Stem Cells in Ovarian
Cancer Tissues . Our next objective was to determine wheth-
er the prevalence of EOC stem cells has a prognostic value.
For this study, we focused using a single marker and selected
CD44 as a widely accepted marker for the identiﬁcation ofJournal of Oncology 5
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Figure 3: Expression of CD44 and CK18 in multiple clones of ovarian cancer cells. (a)-(b). CD44+ cells also express CK18 as determined by
ﬂow cytometry (a) and western blot analysis (b). Flow cytometer is representative of the eight evaluated clones. EOC stem cells, determined
by either CD44 (c and d) or Ck18 (e and f) expression, are found in clusters surrounded by CD44− or Ck18− negative cancer cells.
ovarian cancer stem cells. Thus, we analyzed CD44 stain-
ing in ovarian cancer tissue sections obtained from 117
patients. The clinical-pathological data of the study cohort
is presented in Table 1.T h em a j o r i t yo ft h ep a t i e n t sw e r e
older than 50 years with histopathologic diagnosis of serous
ovarian cancer. In addition, most of the patients were clas-
siﬁed FIGO stage II and higher, with moderate or poorly
diﬀerentiated tumors (grade > 1) (Table 1). We detected
CD44+ cancer cells in all but one tissue section tested. How-
ever, we observed variability in the number, distribution,
and location of CD44+ cancer cells amongst patients. Of all
patientstested, 39patientshad between1–5%CD44+cancer
cells, 38 patients had >5–10% CD44+ cells, 19 patients had
>10–20%CD44+cells,9patientshad>20–50%CD44+cells,
and 11 patients had >50% CD44+ cells. Only one sample
was negative for CD44 staining. Due to this high variation,
we classiﬁed the samples as low expression of EOC stem
cells if they had less than 20% positive cells (<20% EOC
stem cells) and high expression if the sample had more than
20% positive cells (>20% EOC stem cells). Thus, of the 117
patients, 20 patients were considered high expression and 97
patients were considered low expression (Table 1). We then
determined if the percentage of EOC stem cells has clinical
correlation.6 Journal of Oncology
(a) (b)
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Figure 4: EOC stem cells present unique morphological characteristics. CD44+ EOC stem cells are characterized by high nuclear to cyto-
plasm (N/C) ratio, contain vesicular chromatin pattern, and have prominent nucleoli. The cells can be found as single cells (a) or clusters of
two or more cells (b–d).
3.4. CD44 Levels Inversely Correlate with FIGO Stage and
Tumor Grade . PatientswithFIGOstageItumorshadahigh-
er number of CD44+ EOC stem cells (>20% CD44+ cells)
with 57.1% of the stage I patients expressing >20% CD44+
cells. ForFIGO stages II, III, and IV, 18.2%, 12.9%, and 4.5%
expressed >20% CD44+ cells (Table 1). Thus, a signiﬁcant
percenthad FIGOstageI(P = 0.00025;x2 = 19.2).Similarly,
the majority of patients with grade I tumors showed high
expression of EOC stem cells (>20% CD44+ cells) (P =
0.021, x2 = 7.7, Table 1). High expression of CD44+ EOC
cells was seen in ﬁfty percent, 14.3%, and 12.1% of grade 1,
2, and 3 disease, respectively. This indicates that in patients
with primary disease, tumorstend to havea lowernumber of
CD44+ EOC stem cells as the disease progresses.
3.5. Correlation between Number of CD44+ EOC Stem Cells
and Chemoresponse. We then evaluated whether a correla-
tionexists between percentageof CD44+EOC stemcells and
response to treatment. Allthe patients inthis cohort received
treatment. The 14 patients with FIGO stage I cancer com-
prised 2 patients with stage IA cancer (one clear cell cancer
and one grade 2 serous = patients with adverse histological
features/high risk patients that routinely receive chemother-
apy) and 12 patients with stage IC tumors that according to
guidelinesaretreatedwithadjuvantchemotherapy.Although
itwasonlymarginally statisticallysigniﬁcant, we observedan
obvious trend (P = 0.06) for poorer response rates among
patients with >20% CD44+ EOC stem cells. Only 73% of
these patients had complete or partial response compared to
90% in patients with low number of EOC stem cells (<20%
CD44 positive cells). Similarly, 27% of patients with >20%
positive cells for CD44 had stable or progressive disease dur-
ing or by the end of ﬁrst line carboplatin and paclitaxeltreat-
ment compared to only 10% in the patients with a low num-
ber ofCD44+cells (<20%CD44+ EOCstem cells) (Table 2).
3.6. Correlation between the Number of CD44+ EOC Stem
Cells and Progression-Free Survival. Although a majority of
patientswithearly-stageovariancancerrespondtotreatment
and have a good prognosis, 10% of these patients will recur
inspiteofappropriatedebulkingandchemotherapy.Thus,in
ordertodeterminewhetherthereisacorrelationbetweenthe
presence of EOC stem cells and recurrence, we analyzed our
study population with respect to progression-free survival.Journal of Oncology 7
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Figure 5:AssociationofEOCstemcells withstroma.(a-b)Ck18+EOCstemcells areinclosecontactwiththesurroundingstroma(arrows);
(c) a cluster of Ck18+ EOC stem cells are in close contact with the stroma forming a niche; (d) magniﬁcation of (c) showing the diﬀerent
cellular components: EOC stem cells (in red) in direct contact with the stroma and surrounded by Ck18-negative cancer cells. The arrow
shows the basement membrane between the two compartments.
In multivariate analysis, the percentage of CD44+ EOC stem
cells was independently correlated to progression-free sur-
vival with a hazard ratio of 2.44 (1.08–5.52) 95% CI, toward
shorter survival for patients with high number of EOC stem
cells (Table 3). As anticipated, FIGO stage and residual tu-
mor were also independently correlated to progression-free
survival.
Further subgroup analysis showed that in early-stage
ovarian cancer (FIGO stage I/II), patients with high number
of CD44+ EOC stem cells (>20%) had signiﬁcantly shorter
progression-free survival compared to patients with a low
number of CD44+ cells EOC stem cells (<20%) (P = 0.026)
(Figure 6). In contrast, in patients with advanced-stage ovar-
ian cancer (FIGO stage III/IV), the number of CD44+ EOC
stem cells did not correlate with progression-free sur-vival
(P = 0.95, data not shown).
4.Discussion
We show in this paper that CD44+ EOC stem cells can be
detected in tumor sections obtained from patients with
ovarian cancer. Interestingly, in this retrospective study, we
found that there was an inverse correlation between FIGO
stage/disease grade and the presence of these cells. However,
our ﬁndings show that in early-stage ovarian cancer, patients
with tumors containing >20% CD44+ EOC stem cells had a
shorter progression-free survival compared to patients with
tumors having <20% of these cells. In multivariate analysis,
we found that CD44 positivity was an independent predictor
ofpoorprogression-free survival. Sincehigh levelsofCD44+
EOC stem cells correlated with poor prognosis in early stage
ovarian cancer but not in patients with advanced FIGO
stage, it is possible that the high level of EOC stem cells in
stage I, and II resulted in the observed signiﬁcance in the
multivariate analysis.
The existence of CSC has been demonstrated in several
tumor types such as acute myelogenous leukemia, breast,
pancreatic, and brain tumors [11, 30–33]. These cells are
believed to sustain tumor formation through their self-
renewal and diﬀerentiation potential. In ovarian cancer,
B a p a te ta l .[ 16] reported the isolation and identiﬁcation
of ovarian CSC. Using an in vitro model system comprised8 Journal of Oncology
Table 1: Patient and tumor characteristics and percentage of CD44+ EOC stem cells. Groups are classiﬁed based on their CD44 expression
as tumors containing less than 20% CD44 positive (>20%) or more than 20% CD44 positive cells (<20%).
Characteristics No. of patients % <20% CD44 Cells
N( % )
>20% CD44 Cells
N( % ) P
Age 0.0013
<50 10 8.6 6 (60.0) 4 (40.9)
51–65 54 46.2 40 (74.1) 14 (25.9)
>65 53 45.3 51 (96.2) 2 (3.8)
Median 63.2
Range 32–79
FIGO stage 0.00025
I 14 12.0 6 (42.9) 8 (57.1)
II 11 9.4 9 (81.8) 2 (18.2)
III 70 59.8 61 (87.1) 9 (12.9)
IV 22 18.8 21 (95.5) 1 (4.5)
Tumor grade 0.0209
1 8 6.8 4 (50.0) 4 (50.0)
2 42 35.9 36 (85.7) 6 (14.3)
3 58 49.6 51 (87.9) 7 (12.1)
Not graded (clear cell or
metastatic biopsy) 97 . 7
Histopathologic cell type 0.0760
Serous 100 85.5 86 (86.0) 14 (14.0)
Endometrioid 5 4.3 4 (80.0) 1 (20.0)
Clear cell 8 6.8 5 (62.5) 3 (37.5)
Mucinous 1 0.9 0 (0.0) 1 (100)
Carcinomas
(mixed or undiﬀerentiated) 3 2.6 2 (66.7) 1 (33.3)
Residual postoperative tumor 0.014
≤1cm 56 51.4 42 (75.0) 14 (25.0)
>1cm
(Unknown:8 ) 53 48.6 49 (92.5) 4 (7.5)
CD44 immunostaining
Less than 20% CD44+ cells 97 82.9 NA NA NA
More than 20% CD44+ cells 20 17.1
Table 2: Correlation between percentage of CD44+ EOC stem cells
and response to ﬁrst-line carboplatin/paclitaxel treatment. Groups
are classiﬁed based on their CD44 expression as tumors containing
less than 20% CD44 positive (>20%) or more than 20% CD44
positive cells (<20%).
Percentage of CD44+ EOC stem cells
<20% CD44 Cells
(n = 84)
>20% CD44 Cells
(n = 15) P
0.06
CR + PR
(n = 87) 76 (90%) 11 (73%)
SD + PD
(n = 12) 8 (10% ) 4 (27%)
of 19 spontaneously immortalized clones derived from an
advanced-gradepatient,theauthorsdemonstratedtheability
of 2 clones to form spheroids and recapitulate the human
tumor in nude mice. These cells were shown to express
CD44, E-cadherin, and the stem cell factors Nestin, Nanong,
and Oct-4. In a separate study, Zhang et al. [18]r e p o r t e dt h e
tumor-initiating capacity of CD44+/CD117+ovarian cancer
cells in mice.
The identiﬁcation of CSC is done based on the presence
of extracellular markers that are thought to be stem cell
speciﬁc. Some of the most commonly identiﬁed markers
are CD133, CD44, and CD24, which are found in breast,
prostate,pancreas, andovarian cancer.Althoughthesemark-
ers are thought to be indicative of CSC phenotype, it is not
clear whether they are universal markers and if it is a char-
acteristic of CSC derived from all type of tumors. That is the
case for ovarian cancer where multiple markers have been
described for the isolated tumor initiating cells. A potential
explanation forthe discrepancy couldbe duetostudiesusing
cancercellslineswhich maynotrepresenttheoriginaltumor.Journal of Oncology 9
Table 3: Multivariate analyses of progression-free survival in 117 ovarian cancer patients.
Clinicopathological
characteristics B regression coeﬃcient Standard Error (B) Hazard ratio 95% CI (Hazard ratio) P value∗
Age −0.025 0.014 0.98 0.95–1.00 0.083
FIGO stage
I/II 1.00
III/IV 1.814 0.502 6.13 2.29–16.4 0.0003
Grade
11 . 0 0
2 0.750 0.778 2.12 0.46–9.73 0.34
3 0.617 0.769 1.85 0.41–8.36 0.42
Residual tumor
≤1cm 1.00
>cm 0.858 0.277 2.35 0.83–2.30 0.002
% E O C stem cells
<20% CD44 Cells 1.00
>20% CD44 Cells 0.893 0.416 2.44 1.08–5.52 0.032
∗Cox regression model.
FIGO stage I/II. P = 0.026
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Figure 6: Progression-free survival in ovarian cancer patients with
stage I/II. In early-stage ovarian cancer (FIGO stage I/II), patients
with a high percentage of CD44+ positive EOC stem cells (>20%)
(CD44 High) had signiﬁcantly shorter progression-free survival
compared to patients with a low number of CD44+ EOC stem cells
(CD 44 low) (P = 0.026).
However, it may also be a result of the heterogeneous nature
of ovarian cancer and its multiple sources of origin [34,
35]. An ovarian cancer stem cell originated in the fallopian
tube might present diﬀerent surface markers than a CSC
originated from the endometrium or the surface epithelium
of the ovaries.
Our group previously identiﬁed at least two types of
EOC cells based on their response to chemotherapy: Type
I-chemoresistant and Type II-chemosensitive EOC cells [36,
37]. Further characterization showed that these cells have
additional diﬀerences in terms of growth, cytokine produc-
tion, and intracellular markers [38]. While Type II EOC cells
represent the “classical” ovarian cancer cells characterized
by fast growth and lack of cell to cell contact inhibition,
Type I EOC cells are characterized by slower growth, which
is inhibited upon cell to cell contact. In addition, Type I,
but not Type II, EOC cells have constitutive NF-kB activity
and constitutively secrete IL6, IL8, MCP-1, and GROα [14].
Gene expression microarray analysis comparing these two
types of cells further showed that Type I EOC cells expressed
signiﬁcantly higher levelsofthe stemcell markers, CD44and
SSEA-4, the TLR adapter protein MyD88, Cytokeratin 18,
Trop-1, and others [14]. In contrast, Type II EOC cells were
negative for all these markers.
These ﬁndings suggest that Type I EOC cells may rep-
resent the population that has stem-like properties. Indeed,
we demonstrated that Type I EOC cells, as selected by CD44,
are able to form xenografts in mice and resulted in tumors
containing both CD44+ and CD44− cells. In this study, we
evaluated additional markers present in our recently isolated
CD44+ EOC cells [14]. We observed that these cells are also
CK18+, a marker associated with epithelium of the fallopian
tubes.
Aldehyde dehydrogenase (ALDH1) has been proven use-
ful for the identiﬁcation of cancer stem cells, including ovar-
ian cancer [19]; therefore, we evaluated the expression of
ALDH1 in the identiﬁed CD44+ EOC stem cell clones. We
found high levels of ALDH on EOC stem cells by immuno-
ﬂuorescence, suggesting that ALDH1 could be used also as a
marker to monitor the presence of cancer stem cells.
We described additional evidence in support of previous
ﬁndings showing that Type I EOC cells (CD44+) are the
source of Type II cells or CD44−. To closely monitor EOC
stem cell fate and function in mice, we labeled CD44+ cells10 Journal of Oncology
with dual-function reporter genes encoding the sequence
of the ﬂorescence protein Tomato (red color). Using a
xenograft tumor model, we demonstrated that following
injection ofdoublepositiveCD44+/Tomato+cells, thenewly
formed tumor originating from these double positive cells is
characterized byCD44−cells,whichmaintain theexpression
of the ﬂuorescent protein Tomato. This demonstrates that
CD44+ EOC stem cells can both self-renew and diﬀerentiate
[39]. Moreover, microscopic analysis of the xenografts
showed that CD44+ EOC cells were able to recapitulate
the morphology of the original tumor [14]. Finally, in vitro
diﬀerentiation of the chemoresistant CD44+ EOC stem cells
resulted in chemosensitive cultures that have lost CD44. In
this study, we showed that the presence of CD44+ EOC
stem cells correlates with poor prognosis. Since the CD44+
cells are in general more chemoresistant, they can persist
after chemotherapy and may initiate recurrence upon the
completion of treatment.
We found EOC stem cells localized in clusters sur-
rounded by diﬀerentiated ovarian cancer cells and in close
proximity with the stroma. Emerging evidence indicates that
a specialized environment, the stem cell niche, is one of the
factors regulating stem cell maintenance and self-renewal
[9,40,41].Alterationstothestroma may aﬀectthecontrolof
self-renewal [30].This isillustrated by the studiesofYauch et
al. who showed that inhibition of Hh pathway in pancreatic
associated stroma cells resulted in suppression of tumor
growth [42]. In contrast, inhibition of the same pathway in
thecancercellsdidnothaveanyeﬀectontumorgrowth.This
suggests that the variation on the number of cancer stem
cells observed in our study may be the result of alteration
in the interaction between the stroma and the cancer stem
cells. A functional stroma might maintain a small pool of
cancer stem cells while promoting diﬀerentiation. However,
disruption of the stroma-cancer stem cells interaction might
lead to uncontrolled self-renewal and signiﬁcant increase in
the pool of chemoresistant EOC stem cells and consequent
poor prognosis.
CD44 is a cell surface glycoprotein receptor with several
isoforms [43]. All isoforms are encoded by a single gene
and result from alternative splicing. CD44 is expressed
by most cells, including hematopoietic cells and tumors.
Several studies have evaluated CD44 expression in ovarian
cancer tumors and correlated with survival outcome. CD44
expression has been reported to correlate with a signiﬁcantly
shorter disease survival than for patients with CD44 negative
tumors[44,45].However,studiesinvestigatingCD44expres-
sion in terms of IHC and survival are contradictory [46,
47]. Diﬀerences between these studies that could account
for diﬀerences in their ﬁndings could be attributed to
technical factors, including the use of diﬀerent monoclonal
or polyclonal antibodies that exhibit variable eﬃcacy in
paraﬃn-embedded tissues and to diﬀerent methods used for
assessment of immunostaining. In this study, we focused on
CD44 expression as a marker of the cancer stem cells and its
evaluation is based on the percentage of ovarian cancer stem
cells present in the tumor.
CD44 is more than a marker; this transmembrane re-
ceptor has been shown to be important in various cellular
processes such as growth, diﬀerentiation, and motility [43].
The most studied function of CD44 is its role as the receptor
for hyaluronan (HA) [48]. Binding of HA to CD44 controls
cell-cell interactions, as well as interactions of the cell
with the extra-cellular matrix. Furthermore, it can function
as detector of tissue damage and promote tissue repair.
Therefore, it is possible that CD44 expression in EOC stem
cellsmightplayacentralroleinself-renewal andtheresponse
to tissue damage.
5.Conclusion
We describe the intratumoral localization of EOC stem cells
inovarian tumorsamples. Weshowtheirexistenceas clusters
located close to the stroma forming what has been described
as the CSC “niche”. Furthermore, we demonstrate a correla-
tion between the percentage of CD44+ EOC stem cells and
survival in early-stage ovarian cancer. Although it is a small
cohort, especially the early stage, the ﬁndings from this study
are important since they suggest that quantiﬁcation of the
number of EOC stem cells present in the tumor can be used
as a predictor of disease and could be applied for treatment
selection in early-stage ovarian cancer.
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